688076 诺泰生物
未开盘 07-16 09:30:00
资讯
新帖
简况
减肥药概念盘中拉升，蓝晓科技涨2.40%
市场透视 · 07-15 01:41
减肥药概念盘中拉升，蓝晓科技涨2.40%
非酒精性脂肪性肝炎(NASH)概念盘中跳水，诺泰生物跌1.31%
市场透视 · 07-14 01:37
非酒精性脂肪性肝炎(NASH)概念盘中跳水，诺泰生物跌1.31%
【减肥药概念持续走高，常山药业“20cm”涨停】 减肥药概念持续走高，常山药业“20cm”涨停，凯莱英、美迪西、金凯生科、博瑞医药、诺泰生物、纳微科技等跟涨。
金融界 · 07-11
【减肥药概念持续走高，常山药业“20cm”涨停】 减肥药概念持续走高，常山药业“20cm”涨停，凯莱英、美迪西、金凯生科、博瑞医药、诺泰生物、纳微科技等跟涨。
诺泰生物2025上半年最高预盈3.3亿 财务稳健首季经营现金流增85%
长江商报 · 07-08
诺泰生物2025上半年最高预盈3.3亿 财务稳健首季经营现金流增85%
诺泰生物：2025年半年度预计归属于母公司所有者的净利润为30000-33000万元，同比增长32.06%-45.27%
市场资讯 · 07-07
诺泰生物：2025年半年度预计归属于母公司所有者的净利润为30000-33000万元，同比增长32.06%-45.27%
每周股票复盘：诺泰生物（688076）预计2025年上半年净利润达3亿至3.3亿
证券之星 · 07-05
每周股票复盘：诺泰生物（688076）预计2025年上半年净利润达3亿至3.3亿
减肥药概念盘中拉升，圣诺生物涨7.31%
市场透视 · 07-04
减肥药概念盘中拉升，圣诺生物涨7.31%
创新药板块逆势上行，机构称创新药为核心投资主线
每日经济新闻 · 07-04
创新药板块逆势上行，机构称创新药为核心投资主线
CRO概念盘中拉升，诺泰生物涨4.11%
市场透视 · 07-04
CRO概念盘中拉升，诺泰生物涨4.11%
非酒精性脂肪性肝炎(NASH)概念盘中拉升，诺泰生物涨3.58%
市场透视 · 07-04
非酒精性脂肪性肝炎(NASH)概念盘中拉升，诺泰生物涨3.58%
减肥需求成增长引擎 诺泰生物上半年净利增加32.06%至45.27%
e公司 · 07-03
减肥需求成增长引擎 诺泰生物上半年净利增加32.06%至45.27%
诺泰生物123万股完成归属登记，将于7月9日上市流通
财中社 · 07-03
诺泰生物123万股完成归属登记，将于7月9日上市流通
诺泰生物(688076.SH)发预增，预计半年度归母净利润3亿元到3.3亿元，同比增加32.06%到45.27%
智通财经 · 07-03
诺泰生物(688076.SH)发预增，预计半年度归母净利润3亿元到3.3亿元，同比增加32.06%到45.27%
非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨1.64%
市场透视 · 07-01
非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨1.64%
销售费用多年居高不下 上交所五问前沿生物
中国经营网 · 06-27
销售费用多年居高不下 上交所五问前沿生物
发展加速度——诺泰生物CPHI China 2025
诺泰生物 · 06-26
发展加速度——诺泰生物CPHI China 2025
诺泰生物06月24日主力净流入780.0万元 散户资金抛售
市场透视 · 06-24
诺泰生物06月24日主力净流入780.0万元 散户资金抛售
减肥药概念盘中拉升，常山药业涨3.94%
市场透视 · 06-24
减肥药概念盘中拉升，常山药业涨3.94%
诺泰生物涨5.70%，开源证券一个月前给出“买入”评级
证券之星 · 06-20
诺泰生物涨5.70%，开源证券一个月前给出“买入”评级
非酒精性脂肪性肝炎(NASH)概念盘中跳水，诺泰生物跌3.23%
市场透视 · 06-19
非酒精性脂肪性肝炎(NASH)概念盘中跳水，诺泰生物跌3.23%
加载更多
公司概况
公司名称：
江苏诺泰澳赛诺生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2021-05-20
主营业务：
江苏诺泰澳赛诺生物制药股份有限公司的主营业务是聚焦多肽药物及小分子化药进行自主研发与定制研发生产。公司的主要产品是定制类产品及技术服务、自主选择产品。
发行价格：
15.57
{"stockData":{"symbol":"688076","market":"SH","secType":"STK","nameCN":"诺泰生物","latestPrice":40.46,"timestamp":1752627920000,"preClose":40.46,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":316000000,"shares":316000000,"eps":1.5526,"marketStatus":"未开盘","change":0,"latestTime":"07-16 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":1.5526,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752629400000},"marketStatusCode":0,"adr":0,"adjPreClose":40.46,"symbolType":"stock_kcb","openAndCloseTimeList":[[1752629400000,1752636600000],[1752642000000,1752649200000]],"highLimit":44.51,"lowLimit":36.41,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":316051897,"isCdr":false,"pbRate":4.65,"roa":"--","peRate":26.059513,"roe":"5.57%","epsLYR":1.88,"committee":0,"marketValue":12787000000,"turnoverRate":0,"status":2,"floatMarketCap":12787000000},"requestUrl":"/m/hq/s/688076","defaultTab":"news","newsList":[{"id":"2551513218","title":"减肥药概念盘中拉升，蓝晓科技涨2.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551513218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551513218?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:41","pubTimestamp":1752543693,"startTime":"0","endTime":"0","summary":"07月15日，减肥药概念盘中拉升，截至09点41分，减肥药概念整体指数上涨0.51%，报1150.470点。从个股上来看，该概念的成分股中，蓝晓科技涨2.40%，博瑞医药、诺泰生物、众生药业涨幅居前。从资金上来看，截止发稿，减肥药概念主力净流入为-2.20亿，其中众生药业受到资金热捧，主力净流入1104.60万；拉长时间线来看，该板块近20日主力资金净流入-62.69亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509413397a65d41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509413397a65d41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","BK0132","BK0239","300487","688076"],"gpt_icon":0},{"id":"2551873979","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，诺泰生物跌1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551873979","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551873979?lang=zh_cn&edition=full","pubTime":"2025-07-14 09:37","pubTimestamp":1752457031,"startTime":"0","endTime":"0","summary":"07月14日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至09点37分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌0.62%，报1182.970点。从个股上来看，该概念的成分股中，诺泰生物跌1.31%，福瑞股份、众生药业、迈瑞医疗跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-1448.89万，其中迈瑞医疗受到资金热捧，主力净流入556.60万；拉长时间线来看，该板块近20日主力资金净流入-15.66亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071409371195416d33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071409371195416d33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2550605433","title":"【减肥药概念持续走高，常山药业“20cm”涨停】 减肥药概念持续走高，常山药业“20cm”涨停，凯莱英、美迪西、金凯生科、博瑞医药、诺泰生物、纳微科技等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550605433","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550605433?lang=zh_cn&edition=full","pubTime":"2025-07-11 09:57","pubTimestamp":1752199038,"startTime":"0","endTime":"0","summary":"减肥药概念持续走高，常山药业“20cm”涨停，凯莱英、美迪西、金凯生科、博瑞医药、诺泰生物、纳微科技等跟涨。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/11095751620113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688690","688202","BK0172","688166","BK0229","BK1191","LU2488822045.USD","002821","BK0070","300255","BK0216","301509","06821","BK0239","688076","BK0132","LU1328615791.USD"],"gpt_icon":0},{"id":"2549561508","title":"诺泰生物2025上半年最高预盈3.3亿 财务稳健首季经营现金流增85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549561508","media":"长江商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549561508?lang=zh_cn&edition=full","pubTime":"2025-07-08 08:15","pubTimestamp":1751933756,"startTime":"0","endTime":"0","summary":"2025年半年度业绩预告显示，报告期内，诺泰生物预计2025年半年度实现归母净利润3亿到3.3亿元，同比增加32.06%到45.27%；扣非净利润为3亿到3.3亿元，同比增加30.78%到43.86%。同时，诺泰生物保持稳健的财务结构，2025年一季度末，公司总资产54.39亿元，比上年度末增长7.11%；经营活动产生的现金流量净额1.45亿元，同比增长85.23%。自上市以来，诺泰生物每年向股东发放现金红利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708082032953a1fe9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708082032953a1fe9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239","159399"],"gpt_icon":0},{"id":"2549637721","title":"诺泰生物：2025年半年度预计归属于母公司所有者的净利润为30000-33000万元，同比增长32.06%-45.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549637721","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549637721?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:03","pubTimestamp":1751850180,"startTime":"0","endTime":"0","summary":"来源：Gangtise投研诺泰生物2025年半年度业绩预告显示，预计归属于母公司所有者的净利润为30000-33000万元，同比增长32.06%-45.27%。扣除非经常性损益后，净利润预计也为30000-33000万元，同比增长30.78%-43.86%。与2024年上半年相比，预计净利润增加7284-10284万元。业绩增长主要得益于公司以“时间领先、技术领先”的经营理念，发挥学科交叉及国际化BD团队的竞争优势，持续扩大优质客户规模，报告期内公司多肽原料药等销售收入实现较大增长。责任编辑：郝欣煜","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707090420a699ca72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707090420a699ca72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076"],"gpt_icon":0},{"id":"2549344786","title":"每周股票复盘：诺泰生物（688076）预计2025年上半年净利润达3亿至3.3亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2549344786","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549344786?lang=zh_cn&edition=full","pubTime":"2025-07-06 02:15","pubTimestamp":1751739314,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘，诺泰生物报收于39.01元，较上周的37.72元上涨3.42%。本周，诺泰生物7月4日盘中最高价报39.8元。本周关注点业绩披露要点：诺泰生物预计2025年上半年净利润为3亿元至3.3亿元，同比增长32.06%到45.27%公司公告汇总：诺泰生物完成2023年限制性股票激励计划第二个归属期的股份归属登记工作，上市股数为1232616股业绩披露要点诺泰生物发布业绩预告，预计2025年1-6月扣非后净利润盈利3亿元至3.3亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"gpt_icon":0},{"id":"2548356477","title":"减肥药概念盘中拉升，圣诺生物涨7.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548356477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548356477?lang=zh_cn&edition=full","pubTime":"2025-07-04 13:01","pubTimestamp":1751605282,"startTime":"0","endTime":"0","summary":"07月04日，减肥药概念盘中拉升，截至13点01分，减肥药概念整体指数上涨1.00%，报1118.610点。从个股上来看，该概念的成分股中，圣诺生物涨7.31%，翰宇药业、诺泰生物2只股涨幅超过5%。从资金上来看，截止发稿，减肥药概念主力净流入为-2.86亿，其中恒瑞医药受到资金热捧，主力净流入1.37亿；拉长时间线来看，该板块近20日主力资金净流入-84.31亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704130122a72e0c87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704130122a72e0c87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","01276","688117","688076"],"gpt_icon":0},{"id":"2548330540","title":"创新药板块逆势上行，机构称创新药为核心投资主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2548330540","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548330540?lang=zh_cn&edition=full","pubTime":"2025-07-04 10:29","pubTimestamp":1751596152,"startTime":"0","endTime":"0","summary":"7月4日早盘，A股整体小幅回落，医药板块逆势上行，科创医药ETF基金涨幅超0.5%。公开信息显示，科创医药ETF基金跟踪上证科创板生物医药指数，囊括科创板中创新药、国产高端医疗设备、生命科学与生物技术等领域的专精特新公司。伴随政策对创新药保驾护航、创新药获批上市井喷、出海以及国产替代，医药行业有望迎来机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704103134a4ce73ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704103134a4ce73ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688331","688091","688506","159992","688520","688505","BK0239","688076"],"gpt_icon":0},{"id":"2548332218","title":"CRO概念盘中拉升，诺泰生物涨4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548332218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548332218?lang=zh_cn&edition=full","pubTime":"2025-07-04 09:50","pubTimestamp":1751593858,"startTime":"0","endTime":"0","summary":"07月04日，CRO概念盘中拉升，截至09点50分，CRO概念整体指数上涨0.51%，报477.930点。从个股上来看，该概念的成分股中，诺泰生物涨4.11%，圣诺生物、博济医药、皓元医药涨幅居前。从资金上来看，截止发稿，CRO概念主力净流入为-2067.64万，其中华测检测受到资金热捧，主力净流入1168.69万；拉长时间线来看，该板块近20日主力资金净流入-43.42亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507040950589535e4e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507040950589535e4e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2548332205","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，诺泰生物涨3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548332205","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548332205?lang=zh_cn&edition=full","pubTime":"2025-07-04 09:49","pubTimestamp":1751593742,"startTime":"0","endTime":"0","summary":"07月04日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至09点48分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨0.61%，报1154.630点。从个股上来看，该概念的成分股中，诺泰生物涨3.58%，康弘药业、微芯生物、迈瑞医疗涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为1391.18万，其中迈瑞医疗受到资金热捧，主力净流入5283.96万；拉长时间线来看，该板块近20日主力资金净流入-8.25亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070409490297994967&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070409490297994967&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239","688076"],"gpt_icon":0},{"id":"2548832993","title":"减肥需求成增长引擎 诺泰生物上半年净利增加32.06%至45.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548832993","media":"e公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548832993?lang=zh_cn&edition=full","pubTime":"2025-07-03 20:00","pubTimestamp":1751544000,"startTime":"0","endTime":"0","summary":"诺泰生物7月3日晚间公告，经财务部门初步测算，公司今年上半年实现净利润3亿元到3.3亿元，同比增加32.06%到45.27%。去年诺泰生物原料药及中间体业务实现收入9.4亿元，同比增长127.0%；期内业务毛利率为76.7%，同比提升6.7个百分点，实现收入和利润的高速扩容。今年一季度，诺泰生物实现营业收入5.7亿元，同比增长59%；归母净利润1.5亿元，同比增长130%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703200130a72cb5b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703200130a72cb5b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2548309805","title":"诺泰生物123万股完成归属登记，将于7月9日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2548309805","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548309805?lang=zh_cn&edition=full","pubTime":"2025-07-03 18:29","pubTimestamp":1751538585,"startTime":"0","endTime":"0","summary":"7月3日，诺泰生物（688076）发布公告，2023年限制性股票激励计划第二个归属期123万股完成归属登记，流通日期定于2025年7月9日。公告中提到，本次股票归属登记已完成，涉及62名激励对象，归属的股票来源为公司向激励对象定向发行A股普通股。归属后，公司股本总数由3.15亿股增加至3.16亿股，但未导致公司控制权发生变更。此外，预计归属后公司2024年基本每股收益将因总股本增加而相应摊薄。2025年一季度，诺泰生物实现收入5.66亿元，归母净利润1.53亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070318300895351dcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070318300895351dcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2548032978","title":"诺泰生物(688076.SH)发预增，预计半年度归母净利润3亿元到3.3亿元，同比增加32.06%到45.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548032978","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548032978?lang=zh_cn&edition=full","pubTime":"2025-07-03 18:28","pubTimestamp":1751538482,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺泰生物(688076.SH)发布公告，公司预计2025年半年度实现归属于母公司所有者的净利润为3亿元到3.3亿元，与上年同期(法定披露数据)相比，将增加7284万元到10,284万元，同比增加32.06%到45.27%。公司以“时间领先、技术领先”的经营理念，发挥学科交叉及国际化BD团队的竞争优势，持续扩大优质客户规模，报告期内公司多肽原料药等销售收入实现较大增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺泰生物(688076.SH)发预增，预计半年度归母净利润3亿元到3.3亿元，同比增加32.06%到45.27%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688076"],"gpt_icon":0},{"id":"2548047990","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，微芯生物涨1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548047990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548047990?lang=zh_cn&edition=full","pubTime":"2025-07-01 09:35","pubTimestamp":1751333753,"startTime":"0","endTime":"0","summary":"07月01日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至09点35分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨0.53%，报1111.940点。从个股上来看，该概念的成分股中，微芯生物涨1.64%，诺泰生物、康弘药业、华东医药涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为1858.09万，其中迈瑞医疗受到资金热捧，主力净流入1612.43万；拉长时间线来看，该板块近20日主力资金净流入-7.36亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070109355397954156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070109355397954156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","688321","BK0239"],"gpt_icon":0},{"id":"2546724853","title":"销售费用多年居高不下 上交所五问前沿生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2546724853","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546724853?lang=zh_cn&edition=full","pubTime":"2025-06-28 04:54","pubTimestamp":1751057640,"startTime":"0","endTime":"0","summary":"针对上交所2024年年报问询函，6月21日前沿生物进行了回复。同时，销售费用占营收的比例超过六成加剧了前沿生物的亏损。销售费用高企2024年，前沿生物销售费用为8634.4万元，同比增长33.3%。2018年，在艾可宁上市初期，销售工作处于起步阶段，销售收入规模整体较小，前沿生物销售费用是营业收入的4倍。截至目前，艾可宁仍是前沿生物的主要收入来源。创新药毛利率明显偏低前沿生物连续多年处于亏损状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506280455409791cf9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506280455409791cf9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","688221","BK0239"],"gpt_icon":0},{"id":"2546030789","title":"发展加速度——诺泰生物CPHI China 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2546030789","media":"诺泰生物","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546030789?lang=zh_cn&edition=full","pubTime":"2025-06-26 17:07","pubTimestamp":1750928877,"startTime":"0","endTime":"0","summary":"2025年6月24日-26日，第二十三届世界制药原料中国展在上海新国际博览中心盛大举行。展会期间，诺泰生物与全球药企展开高效对接与深度交流，推动多项合作意向加速落地。步履不停，创新不止，诺泰生物以更坚定步伐，携手全球伙伴，加速创新成果转化，为人类健康事业创造价值。撰稿人：Jennie关于诺泰生物诺泰生物于2009年成立，2021年科创板上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626172615a71e9bda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626172615a71e9bda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2545840179","title":"诺泰生物06月24日主力净流入780.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2545840179","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545840179?lang=zh_cn&edition=full","pubTime":"2025-06-24 15:20","pubTimestamp":1750749616,"startTime":"0","endTime":"0","summary":"06月24日, 诺泰生物股价涨1.88%，报收38.47元，成交金额3.8亿元，换手率3.12%，振幅3.47%，量比0.97。诺泰生物今日主力资金净流入780.0万元，上一交易日主力净流出411.0万元。该股近5个交易日上涨2.21%，主力资金累计净流出2373.8万元；近20日主力资金累计净流出1.8亿元，其中净流出天数为13日。|06月24日主力加仓幅度排名||#|股票简称|主力净额占比|#|华铭智能|7.31%|#|星源卓镁|6.19%|#|信德新材|6.16%|#|...|...|#1642|诺泰生物|0.06%|诺泰生物所在的化学制药行业，今日主力净流入5746万元，行业排名55/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624164626a71ae195&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624164626a71ae195&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2545478953","title":"减肥药概念盘中拉升，常山药业涨3.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545478953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545478953?lang=zh_cn&edition=full","pubTime":"2025-06-24 10:25","pubTimestamp":1750731914,"startTime":"0","endTime":"0","summary":"06月24日，减肥药概念盘中拉升，截至10点25分，减肥药概念整体指数上涨1.00%，报1064.340点。从个股上来看，该概念的成分股中，常山药业涨3.94%，皓元医药、阳光诺和、诺泰生物涨幅居前。从资金上来看，截止发稿，减肥药概念主力净流入为239.50万，其中华东医药受到资金热捧，主力净流入5546.81万；拉长时间线来看，该板块近20日主力资金净流入-89.26亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624102514a4ba95e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624102514a4ba95e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0172","688131","688621","BK0070","300255","BK0239","688076"],"gpt_icon":0},{"id":"2544149408","title":"诺泰生物涨5.70%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2544149408","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544149408?lang=zh_cn&edition=full","pubTime":"2025-06-20 16:27","pubTimestamp":1750408029,"startTime":"0","endTime":"0","summary":"今日诺泰生物涨5.70%，收盘报37.83元。2025年4月24日，开源证券研究员余汝意,汪晋发布了对诺泰生物的研报《公司信息更新报告：业绩表现持续亮眼，看好多肽原料药龙头全年机会》，该研报对诺泰生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为86.17%。此外，民生证券研究员王班,杨涛，信达证券研究员唐爱金,贺鑫近期也对该股发布了研报，同样给出“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000023500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","161027"],"gpt_icon":0},{"id":"2544135643","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，诺泰生物跌3.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544135643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544135643?lang=zh_cn&edition=full","pubTime":"2025-06-19 10:55","pubTimestamp":1750301741,"startTime":"0","endTime":"0","summary":"06月19日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至10点55分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌1.02%，报1071.840点。从个股上来看，该概念的成分股中，诺泰生物跌3.23%，微芯生物、康弘药业、众生药业跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-5826.47万，其中华东医药受到资金热捧，主力净流入2010.75万；拉长时间线来看，该板块近20日主力资金净流入-9.88亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506191055419522a5dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506191055419522a5dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752627926462,"stockEarnings":[{"period":"1week","weight":0.0575},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.187},{"period":"6month","weight":0.1486},{"period":"1year","weight":-0.1647},{"period":"ytd","weight":0.1066}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.0379},{"period":"3month","weight":0.0699},{"period":"6month","weight":0.0831},{"period":"1year","weight":0.1785},{"period":"ytd","weight":0.0457}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏诺泰澳赛诺生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12886人(较上一季度减少5.10%)","perCapita":"24526股","listingDate":"2021-05-20","address":"江苏省连云港市连云区经济技术开发区临浦路28号","registeredCapital":"31605万元","survey":" 江苏诺泰澳赛诺生物制药股份有限公司的主营业务是聚焦多肽药物及小分子化药进行自主研发与定制研发生产。公司的主要产品是定制类产品及技术服务、自主选择产品。","listedPrice":15.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺泰生物(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺泰生物(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺泰生物,688076,诺泰生物股票,诺泰生物股票老虎,诺泰生物股票老虎国际,诺泰生物行情,诺泰生物股票行情,诺泰生物股价,诺泰生物股市,诺泰生物股票价格,诺泰生物股票交易,诺泰生物股票购买,诺泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺泰生物(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺泰生物(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}